Products for Research Use Only

Cyclic (YCDGFYACYMDV)

CAT: 0804-HY-P10793Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P10793Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cyclic (YCDGFYACYMDV) is a HER2 signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to HER2 on cancer cells. This transformation disrupts HER2 dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis) . The inhibitory effects on HER2 positive breast cancer have been demonstrated to be effective in a murine xenograft model[1].
CAS Number
535959-77-4
UNSPSC
12352209
Target
Apoptosis; EGFR
Related Pathways
Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O=C(N[C@@H](CSSC[C@@H](C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)=O)NC2=O)C(N[C@@H](CC(O)=O)C(NCC(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CC=C(C=C4)O)C(N[C@H]2C)=O)=O)=O)=O)=O)[C@H](CC5=CC=C(C=C5)O)N
Molecular Formula
C65H82N12O20S3
Molecular Weight
1447.61
References & Citations
[1]Zhang L, et al. Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. Nat Nanotechnol. 2020 Feb;15 (2) :145-153.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
ErbB2/HER2